12.23.18
solriamfetol
![](https://healthproblemsnews.com/wp-content/uploads/sites/5/2018/04/NjHM5GAIBkRRZatXItDi-150x150.jpg)
DUBLIN, Dec. 21, 2018 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for solriamfetol as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).